These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28377078)

  • 21. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process.
    Trejo SR; Hotta JA; Lebing W; Stenland C; Storms RE; Lee DC; Li H; Petteway S; Remington KM
    Vox Sang; 2003 Apr; 84(3):176-87. PubMed ID: 12670366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
    Li Z; Gaurav M; Yel L
    Pulm Pharmacol Ther; 2023 Dec; 83():102265. PubMed ID: 37923165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Thrombate III®, a pasteurized and nanofiltered therapeutic human antithrombin concentrate.
    Cai K; Osheroff WP; Buczynski G; Hotta J; Lang J; Elliott E; Lee DC; Roth NJ
    Biologicals; 2014 May; 42(3):133-8. PubMed ID: 24477183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line.
    Wang Z; Hilder TL; van der Drift K; Sloan J; Wee K
    Anal Biochem; 2013 Jun; 437(1):20-8. PubMed ID: 23462539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells.
    Ross D; Brown T; Harper R; Pamarthi M; Nixon J; Bromirski J; Li CM; Ghali R; Xie H; Medvedeff G; Li H; Scuderi P; Arora V; Hunt J; Barnett T
    J Biotechnol; 2012 Dec; 162(2-3):262-73. PubMed ID: 23036927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New process for purifying high purity α1-antitrypsin from Cohn Fraction IV by chromatography: A promising method for the better utilization of plasma.
    Huangfu C; Zhang J; Ma Y; Jia J; Lv M; Zhao X; Zhang J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1046():156-164. PubMed ID: 28183045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
    Cai K; Gröner A; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gajardo R; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Lee DC; Moscardini M; Pölsler G; Roth NJ
    Transfusion; 2013 Sep; 53(9):1894-905. PubMed ID: 23252676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of alpha 1-proteinase inhibitor (human).
    Hein RH; Van Beveren SM; Shearer MA; Coan MH; Brockway WJ
    Eur Respir J Suppl; 1990 Mar; 9():16s-20s. PubMed ID: 2340046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Biochemical Efficacy of an α
    Li Z; Franke RM; Morris DN; Yel L
    Pulm Ther; 2022 Sep; 8(3):311-326. PubMed ID: 36001294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and purification of recombinant human alpha1-proteinase inhibitor and its single amino acid substituted variants in Escherichia coli for enhanced stability and biological activity.
    Agarwal S; Jha S; Sanyal I; Amla DV
    J Biotechnol; 2010 May; 147(1):64-72. PubMed ID: 20346993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yield improvement for manufacture of alpha-proteinase inhibitor.
    Zimmerman TP
    Vox Sang; 2006 Nov; 91(4):309-15. PubMed ID: 17105606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification of alpha-1-proteinase inhibitor. Preparation and properties of a therapeutic concentrate.
    Coan MH
    Am J Med; 1988 Jun; 84(6A):32-6. PubMed ID: 3260071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non enzymatic glycosylation of alpha-1-proteinase inhibitor of human plasma.
    Phadke M; Billimoria FR; Ninjoor V
    J Postgrad Med; 1998; 44(2):29-34. PubMed ID: 10703566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep.
    Smith RM; Traber LD; Traber DL; Spragg RG
    J Clin Invest; 1989 Oct; 84(4):1145-54. PubMed ID: 2794051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
    Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
    Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.